key: cord-0890957-7df29ldl
authors: van den Borst, Bram; Peters, Jeannette B; Brink, Monique; Schoon, Yvonne; Bleeker-Rovers, Chantal P; Schers, Henk; van Hees, Hieronymus W H; van Helvoort, Hanneke; van den Boogaard, Mark; van der Hoeven, Hans; Reijers, Monique H; Prokop, Mathias; Vercoulen, Jan; van den Heuvel, Michel
title: Comprehensive health assessment three months after recovery from acute COVID-19
date: 2020-11-21
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1750
sha: 87436d2db463696e7676358b84ec07de7417a3cd
doc_id: 890957
cord_uid: 7df29ldl

BACKGROUND: Long-term health sequelae of COVID-19 may be multiple but have thus far not been systematically studied. METHODS: All patients discharged after COVID-19 from the Radboud university medical centre, Nijmegen, The Netherlands, were consecutively invited to a multidisciplinary outpatient facility. Also, non-admitted patients with mild disease but with symptoms persisting >6 weeks could be referred by general practitioners. Patients underwent a standardized assessment including measurements of lung function, chest CT/X-ray, 6-minute walking test, body composition, and questionnaires on mental, cognitive, health status and quality of life (QoL). RESULTS: 124 patients (age 59±14 years, 60% male) were included; 27 with mild, 51 with moderate, 26 with severe and 20 with critical disease. Lung diffusion capacity was below lower limit of normal in 42% of discharged patients. Ninety-nine percent of discharged patients had reduced ground-glass opacification on repeat CT imaging, and normal chest X-rays were found in 93% of patients with mild diseases. Residual pulmonary parenchymal abnormalities were present in 91% of discharged patients, and correlated with reduced lung diffusion capacity. Twenty-two percent had low exercise capacity, 19% low fat-free mass index, and problems in mental and/or cognitive function were found in 36% of the patients. Health status was generally poor, particularly in the domains functional impairment (64%), fatigue (69%) and QoL (72%). CONCLUSIONS: This comprehensive health assessment revealed severe problems in several health domains in a substantial number of ex-COVID-19 patients. Longer follow-up studies are warranted to elucidate natural trajectories and to find predictors of complicated long-term trajectories of recovery.

By 5 November 2020, the World Health Organization (WHO) reported >47 million confirmed Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases worldwide, and the number of daily new cases keeps on increasing [1] . Although the mortality rate is considerable, the vast majority of SARS-CoV-2 infected patients recovers from the acute phase. Long-term health consequences of this coronavirus disease (COVID- 19 ) are yet largely unknown but many patients are likely to experience long-lasting morbidity [2] . Indeed, based on observations from diseases that share COVID-19 characteristics such as Acute Respiratory Distress Syndrome [3] , SARS-CoV [4] , and Q-fever [5] , it is hypothesized that in the long-term a significant number of COVID-19 patients will suffer from lung function impairment, residual pulmonary parenchymal abnormalities, decreased physical capacity, loss of muscle mass, anxiety, depression, cognitive deficits, post-traumatic stress disorder, fatigue, and poor health status. We aimed to comprehensively assess these health domains in patients three months after recovery from acute COVID-19.

This prospective observational study reports data of 124 patients who consecutively attended the COVID-19 aftercare facility at Radboud university medical center (Radboudumc), Nijmegen, The Netherlands. Within The Netherlands, the centre of the outbreak was close to the city of Nijmegen and the Radboudumc treated patients with moderate-to-critical COVID-19 also including patients who were transferred from other regions because of capacity problems. In the initial phase of the outbreak, SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) tests were not readily available for all patients with mild symptoms that did not require hospital admission; they were advised to stay at home in self-quarantine until respiratory symptoms resolved. Patients who had been discharged after inpatient treatment for COVID-19 were consecutively invited to the A c c e p t e d M a n u s c r i p t 5 aftercare facility. Also, general practitioner (GP) referrals of RT-PCR-confirmed or clinically suspect SARS-CoV-2 patients without hospitalization but with symptoms persisting >6 weeks were included.

A standardized health assessment was performed that included questionnaires, physical measurements and multidisciplinary consultations followed by interdisciplinary case discussions. The team consisted of a pulmonologist, geriatrician, infectious diseases specialist, intensive care specialist, nurse practitioner, physiotherapist, psychologist, dietician, and social worker. Data was collected as part of the ongoing prospective observational POST-COVid-19 recovERY (POSTCOVERY) study, which was approved by the local medical ethics committee of Arnhem-Nijmegen, The [7] on admission, and comorbidities were collected from patients' medical records. Social status, education level and smoking status were collected via questionnaires. C-reactive protein, D-dimer, ferritin and leukocyte count at follow-up were collected.

Resting pulse-oximetry was performed in sitting position at least five minutes and breathing room air. Spirometry, single-breath diffusion capacity and body plethysmography [8] [9] [10] were performed and outcomes were expressed according to reference values. Modified Medical Research Council (mMRC) dyspnea scale was assessed [11] . Discharged patients underwent low-dose chest CT imaging at follow-up. Scanning protocol and structured image interpretation by two independent chest radiologists are described in the online supplement. Referred mild disease patients underwent A c c e p t e d M a n u s c r i p t 6 conventional chest X-ray imaging and presence of residual COVID-19 abnormalities were collected from the radiological report.

The degree of frailty was assessed with the Clinical Frailty Scale (CFS) [12] . Scores <5 can be considered as not frail, a score of 5 indicates somewhat frail, and scores >5 indicate frailty. A 6minute walking test (6MWT)[13] was performed and outcomes were expressed according to reference values. Desaturation upon the 6MWT was defined as a fall ≥4% of the resting saturation [14] . Anthropometry was assessed by measuring body height and weight and body mass index (BMI) was calculated as body weight/height 2 . Body composition was assessed by bio-electrical impedance analysis (BIA, Bodystat 500, EuroMedix, Leuven, Belgium) excluding patients with peripheral edema or pacemaker. Fat-free mass index (FFMI) was calculated as fat-free mass/height 2 , and age-, sex-and BMI-specific cut points were applied to determine the proportion of patients with FFMI<lower limit of normal (LLN) [15] . Anxiety and depression were measured by the Hospital Anxiety and Depression Scale (HADS) [16] . The Telephone Interview of Cognitive Status (TICS) [17] was assessed to screen for cognitive impairment and the Cognitive Failure Questionnaire (CFQ) [18] to measure self-reported cognitive functioning. The Post Traumatic Stress Syndrome (PTSS) Checklist DSM-5 (PCL-5) [19] and the Impact of Event Scale-Revised (IES-R) [20] were assessed to screen for PTSS and to measure stress reactions after traumatic events, respectively. Generally accepted cut-off scores were applied to determine abnormal mental or cognitive status (HADS-anxiety>10, HADS-depression>10, TICS<34, CFQ>43, PCL-5>33 and IES-R>33).

A c c e p t e d M a n u s c r i p t 7

Health status was measured and valued with the Short Form Health survey (SF-36) [21] and the Nijmegen Clinical Screening Instrument (NCSI) [22, 23] . The SF-36 is consists of 8 subscales: physical functioning, social functioning, role functioning, role emotional, emotional well-being, energy/fatigue, pain and general health with higher scores indicating better health status. The NCSI is a battery of subscales from questionnaires that was empirically composed such that it provides a detailed measure of health status, while being short enough to be used in usual care. The NCSI measures 22 aspects of three health status domains: symptoms (pain, dyspnea [23] and fatigue[24]), functional impairments (behavioural impairment [25] and subjective impairment [26] ) and quality of life (general QoL [27, 28] , health-related QoL(HRQoL [23] ), and satisfaction with relations [23] ), with higher scores indicating worse health status. These 22 aspects are aggregated into ten dimensions for which cut points for normal, mild problems and severe problems were applied [22] .

Received treatment by allied health care professionals (AHCP) between acute COVID-19 and day of outpatient visit was recorded. Advice following interdisciplinary case discussions was collected and grouped into one or more of the following categories: additional diagnostics, self-management advice, medication advice, specific advice to the GP, new referral to an AHCP, new referral to another medical specialist, and referral to specialized rehabilitation.

Statistical analyses were performed using SPSS statistical software program, version 25.0. Betweengroup comparisons for continuous variables were tested by one-way analysis of variance or Kruskal-Wallis test. Categorical variables were tested with a Chi-square test. If a statistically significant difference was obtained, a post-hoc test was performed applying Bonferroni correction to account M a n u s c r i p t 8 for multiple comparisons. Within-group differences of continuous variables between baseline and follow-up were tested with paired t-tests. Missing data were handled by complete case analysis. A pvalue of <0.05 was considered significant.

Between 23 April and 15 July 2020, 171 consecutively discharged COVID-19 patients were invited to the aftercare facility of whom 97 (57%) attended and were included in the analysis. Reasons for nonattendance are presented in Figure 1 . Compared to discharged patients included in the analysis, non-attendees had similar mean age, sex distribution, mean length of stay and distribution of COVID-19 severity grades (all p>0.05, data not shown). All twenty-seven referred mild disease patients were included. Collectively, this study describes the results of 124 patients. Table 1 provides demographics, acute COVID-19 characteristics, comorbidities, and the timing of outpatient follow-up. Critical disease patients were younger compared to moderate-tosevere disease patients and were predominantly male. Referred mild disease patients were younger than moderate-to-critical disease patients and were predominantly female. Increasing COVID-19 severity grade was paralleled by increases in CT severity scores, length of stay and prevalence of pulmonary embolism. Critical disease patients had a mean (SD) of 15 (8) ICU treatment days.

Twenty-nine percent of moderate-to-critical disease patients had no comorbidities while this was 78% in referred mild disease patients. Critical disease patients had less comorbidity than moderate and severe disease patients. The assessment was performed at a mean (SD) of 13.0 (2.2) weeks after onset of SARS-CoV-2 symptoms and 9.1 (1.6) weeks after discharge. At follow-up, median CRP, Ddimer, ferritin and mean leukocyte count showed normal levels in all the study groups (Online Supplement Table 1 ).

A c c e p t e d M a n u s c r i p t 9 Table 2 provides the data on dyspnea, lung function and CT imaging at follow-up. Referred mild disease patients reported higher mMRC than moderate-to-critical disease patients. Mean (SD) resting oxygen saturation was 96 (1) % and mean spirometric indices were normal across study groups. Mean diffusion capacity of the lungs for carbon monoxide (DLCO) was significantly lower in moderate-to-critical disease patients compared to referred mild disease patients who had normal mean DLCO. Critical disease patients had lowest mean total lung capacity (TLC) and residual volume (RV). Differences in lung function outcomes were unaffected when the 7 patients with chronic obstructive pulmonary disease/ emphysema were excluded (data not shown). Chest X-rays in referred mild disease patients were normal in 93% of cases; 2 patients (7%) had mild signs of bronchial disease. On follow-up CT imaging of discharged patients, 99% of patients had decreased ground-glass opacities (GGO); in 1% GGO was unchanged. Also, extent of residual pulmonary parenchymal abnormalities was significantly lower compared to admission (Figure 2A) . Nine percent of patients had no residual CT pulmonary abnormalities at all, while residual GGO, bronchi(ol)ectasis, lines or bands and radiological signs of fibrosis were present in 86%, 60%, 64%, and 26% of patients, respectively. No patient had signs of active organizing pneumonia and one (moderate disease) patient had minor residual crazy paving. Extent of residual abnormal pulmonary parenchymal involvement was significantly correlated with DLCO ( Figure 2B ). More specifically, presence and number of residual CT items were associated with lower DLCO (Figures 2C-D) . Presence of signs of residual fibrosis was also associated with older age (68 [12] versus 59 [12] in the referred mild disease group. Desaturators had lower DLCO than non-desaturators (65 (16) versus 85 (14) %predicted, p<0.001). Mean FFMI was normal while 19% of all patients had FFMI<LLN. Abnormal HADS-anxiety, HADS-depression, TICS, CFQ, PCL-5 and IES scores were observed in 10%, 12%, 15%, 17%, 7%, and 10% of patients, respectively, with no statistically significant differences between the study groups. 

In the time between recovery from acute SARS-CoV-2 infection and outpatient assessment day, 26% of the study cohort had received treatment by at least one AHCP, in particular critical disease patients (85%), and most frequently by a physiotherapist (Online Supplement Table 2 ). Following interdisciplinary case discussions, additional diagnostics were indicated in 37% of patients and 85% received self-management advice. Medication advice was given in 20% of patients, and in 46% specific advice was given to the respective GPs. New referrals to AHCPs were indicated in 40% of cases, particularly in referred mild disease patients. 16% of patients were referred to another medical specialist, and 4% of the cohort was referred to specialized rehabilitation.

A c c e p t e d M a n u s c r i p t 11

We report the outcomes of a comprehensive health assessment in patients three months after COVID-19. At this point in time, the pulmonary parenchyma has recovered significantly: 99% of patients had lower GGO density and consistent decreases in the extent of affected pulmonary parenchyma were found across COVID-19 severity grades. Residual pulmonary parenchymal abnormalities, however, were present in more than 90% of discharged patients and correlated with the lower lung diffusion capacity after three months. Residual signs suggesting pulmonary fibrosis were found most frequently in those who had critical COVID-19 (50%). It was associated with lower TLC, higher age and exercise-induced desaturation. Our data of decreased DLCO and mildly decreased TLC in recovered COVID-19 patients are in line with previous observations in SARS-CoV [29] and ARDS [30] survivors, and with a previous report in COVID-19 survivors from China [31] .

Our data on radiologically assessed pulmonary recovery from COVID-19 are also in line with emerging reports [32, 33] . The study from Liu et al. showed that four weeks after discharge for moderate COVID-19 significant improvements of the pulmonary parenchyma were observed by CT imaging [32] . Contrary to these authors who found that 65% of patients had full resorption of COVID-19 pulmonary abnormalities after four weeks, we found only 9% of our cohort to be free of residual disease after three months. Potential explanations are that we included COVID-19 patients with severe and critical disease in addition to those with moderate disease, and that we used a different CT technique with high-resolution 0.5 mm slides allowing for more detailed analysis.

Given the level of respiratory insufficiency, relatively long lengths of stay, and mechanical ventilation in those with critical disease -i.e. factors known to decrease physical capacity and muscle mass [34] -, it was hypothesized that we would find low exercise capacity and FFMI at follow-up in our cohort of COVID-19 patients. This hypothesis was further substantiated by the recent publication in an Italian COVID-19 cohort showing low levels of physical functioning at discharge [35] . However, A c c e p t e d M a n u s c r i p t 12 mean 6MWD and FFMI proved to be normal. We speculate that received treatment and natural recovery in the time between acute infection and outpatient visit contributed to this observation. It should, however, be noted that still 22% of our patients low 6MWD and 19% low FFMI, calling for continued attention for these potentially modifiable factors.

About one third of the patients in our cohort had abnormal outcomes on mental status or cognitive function three months after COVID-19. This should raise awareness among health care professionals in COVID-19 aftercare. PTSS generally develops over time and from this perspective formally only can be diagnosed after at least six months [36] , requiring longer follow-up. A pathophysiological role of inflammation underlying psychological and psychiatric symptoms after COVID-19 has been suggested [37] . Considering our data that COVID-19 severity grade does not appear to be associated with differences in mental or cognitive status, whilst particularly the critical disease patients are characterized by a cytokine storm during the acute moment [38], a multifactorial nature of these phenomena requires more investigation.

Our results indicate that a substantial proportion of patients still experiences severe problems in various health domains three months after COVID-19. Referred mild disease patients displayed a female predominance and even more frequently severe problems than discharged patients with moderate-to-critical disease, particularly in the domains of physical functioning, fatigue and quality of life. Since we found no major radiological, lung functional, inflammatory or exercise capacity abnormalities in these referred mild disease patients after three months, explanations for their poor health status remain unclear at this point. Since impaired health status may become chronic as has been found for example ARDS [30] and Q-fever [5] , our observations warrant confirmation in larger cohorts and further long-term investigation.

The strength of our study is the systematic approach and comprehensive assessment of health status in different severity grade COVID-19 patients, allowing for a broad view on COVID-19

sequelae. In addition to survival bias, several factors should be taken into consideration in the A c c e p t e d M a n u s c r i p t 13 interpretation of the current results. Selection bias has occurred since some patients refused hospitalization or ICU admission, or a non-ICU policy was agreed upon following regular shared decision making conversations. Results may be influenced by the lack of data of patients who refused assessment because they were already satisfied with their recovery (15%) or found it too burdensome (11%). Also, the referred mild disease patients included in this analysis form a highly selected subgroup who had health status impairment already for a longer period of time and is therefore not representative for the mild disease COVID-19 population as a whole. Thirteen (48%) of the mild disease and 4 (4%) of the moderate-to-critical disease COVID-19 patients were not laboratory-confirmed but fulfilled clinical criteria and epidemiologic linkage [39] . Considering that symptomatic patients can become seronegative already in the early convalescent phase [40] , we chose to retain these probable COVID-19 patients in the analysis. Our study is limited by its singlecenter design and relatively small number of patients. Inherent in studying long-term effects of an acute outbreak such as COVID-19, standardized baseline measurements of health status and physical measures from before the acute phase are lacking. Several factors, however, suggest that COVID-19

was responsible for the current findings. Indeed, 40% had no relevant comorbidity, only 2% were active smokers, and it was clear from the consultations that the majority of patients marked the infection as the initiating cause of current health problems.

With the SARS-CoV-2 pandemic still ongoing, we are only at the beginning of understanding long-term sequelae of COVID-19. The current observational study described ex-COVID-19 patients at an average of three months after the infection, and showed that while the pulmonary parenchyma has markedly recovered, residual abnormalities were frequently present and were associated with lower lung function. Furthermore, a substantial number of patients suffered from severe problems in different health domains, requiring continued attention from health care providers. Longer followup studies are warranted to elucidate natural trajectories of COVID-19 recovery, to find predictors of complicated long-term trajectories, and to develop strategies to decrease long-term COVID-19 morbidity. 

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

Recovery From Severe COVID-19: Leveraging the Lessons of Survival From Sepsis

Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Persistence of impaired health status of Q fever patients 4 years after the first Dutch outbreak

COVID-19 patients and the radiology departmentadvice from the European Society of Radiology (ESR) and the European Society of Thoracic Imaging (ESTI)

Standardization of Spirometry

ERS/ATS standards for single-breath carbon monoxide uptake in the lung

Standardisation of the measurement of lung volumes

Evaluation of clinical methods for rating dyspnea

A global clinical measure of fitness and frailty in elderly people

6-minute walk testing is more sensitive than maximal incremental cycle testing for detecting oxygen desaturation in patients with COPD

New reference values for body composition by bioelectrical impedance analysis in the general population: results from the UK Biobank

The Telephone Interview for Cognitive Status (Modified): relation with a comprehensive neuropsychological assessment

The Cognitive Failures Questionnaire (CFQ) and its correlates

PTSD Checklist for DSM-5 and Life Events Checklist for DSM-5 with extended A criterion-Nederlandstalige versie. Diemen: Arq Psychotrauma Expert Groep

The Impact of Event Scale -revised

Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations

Development of a battery of instruments for detailed measurement of health status in patients with COPD in routine care: the Nijmegen Clinical Screening Instrument

An Integral assessment framework of health status in chronic obstructive pulmonary disease (COPD)

The Sickness Impact Profile: development and final revision of a health status measure

The development of the 'Quality-of-life for Respiratory Illness Questionnaire (QOL-RIQ)': a diseasespecific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease

Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care

The Satisfaction With Life Scale

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

One-year outcomes in survivors of the acute respiratory distress syndrome

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Chest CT and Clinical Follow-up of Discharged Patients with COVID-19 in Wenzhou City

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

ICU-acquired weakness and recovery from critical illness

Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived the hospitalisation

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

An Atypical Presentation of Novel Coronavirus Disease 2019 (COVID-19)

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

The authors are grateful to: Alicia IJssel-de Schepper, Annemieke Koopman, Bas Robberts, Didy 

A c c e p t e d 

Resting oxygen saturation, mean (SD), %